https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45084 Wed 26 Oct 2022 14:04:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42910 Tue 06 Sep 2022 15:49:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34451 Tue 03 Sep 2019 18:26:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14861 Thu 28 Aug 2014 12:16:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8029 Sat 24 Mar 2018 08:36:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7335 Sat 24 Mar 2018 08:35:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7132 Sat 24 Mar 2018 08:34:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13913 C) and rs5275 (T > C) polymorphisms was performed by real-time polymerase chain reaction using allele-specific probes. Results: Ingestion of any NSAID in the week prior to interview was associated with an elevated risk for ACS: adjusted odds ratio 1.8 (1.2, 2.5). The rs 20417 and rs 5275 polymorphisms were not singly associated with risk for ACS: adjusted odds ratios 1.1 (0.80, 1.5) and 1.2 (0.88, 1.5), respectively. Individually, the polymorphisms did not modify the risk of ACS with the drugs. When analyses were conducted by haplotype, the adjusted odds ratio with celecoxib or rofecoxib in individuals who had one or two copies of the ‘low risk’ haplotype (no GT) was 1.2 (0.29, 5.0), compared with 2.1 (1.1, 4.0) with the ‘high risk’ haplotype (one or two copies of GT). Conclusions: We found little evidence of a gene/drug interaction. We found a statistically non-significant trend toward a lower risk of coronary events with NSAIDs in the presence of the ‘low risk’ haplotype. Even if confirmed, the clinical utility of the finding would be limited as this haplotype is carried by a minority of the population.]]> Sat 24 Mar 2018 08:25:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10024 Sat 24 Mar 2018 08:12:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20929 n=41) and female (n=53). Platelet coagulation parameters including factors I, II, V, VII, VIII, IX, X, vWF:Ag and endogenous thrombin potential were measured at baseline and 4 weeks post supplementation with EPA-rich or DHA-rich oil capsules. Results: We have previously reported that platelet aggregation is specifically reduced by supplementation with EPA in males and DHA in females. This sex-specific effect was also observed for decreases in plasma levels of Factor II (-7.9±3.8%, P=.026), Factor V (-6.5±4.5%, P=.022) and vWF:Ag (-7.3±2.1%, P=.034) and was most pronounced in males supplemented with EPA. In contrast, DHA-mediated reduction in platelet aggregation in females was not accompanied by any significant changes in the coagulation parameters tested. Conclusion: Significant interactions between sex and specific LCn-3PUFA exist to reduce procoagulant activity differentially in males vs. females and could have profound effects on managing risk of thrombotic disease.]]> Sat 24 Mar 2018 08:06:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5432 Sat 24 Mar 2018 07:48:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5366 Sat 24 Mar 2018 07:43:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26254 Sat 24 Mar 2018 07:40:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25283 Sat 24 Mar 2018 07:38:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28169 Palliative Care Needs Assessment Guidelines and Needs Assessment Tool: Progressive Disease-Cancer (NAT: PD-C) on clinical assessment, response and service utilisation. Study setting: Three major oncology treatment centres in NSW, Australia. Study design: Between March 2007 and December 2009, 219 people with advanced cancer were recruited to complete bi-monthly telephone interviews. The intervention, introduced after at least two baseline interviews, involved training health professionals to complete the NAT: PD-C with patients approximately monthly. Data collection: Rates of service use and referrals were compared pre- and post-introduction of the NAT: PD-C. Rates of completion of the tool; its impact on consultation length; and the types of needs and follow-up care to address these were also assessed. Principal findings: The NAT: PD-C had a high rate of completion; identified needs consistent with those self-reported by patients in interviews; and did not alter consultation length. No changes in the number of health professionals seen by patients were found pre- and post-intervention. Conclusion: The NAT: PD-C is an efficient and acceptable strategy for supporting needs-based cancer care that can potentially be incorporated into standard routine care without increasing the burden on care providers.]]> Sat 24 Mar 2018 07:36:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27930 s, was -0.34 and -0.30 respectively, p<0.05) and positively correlated with the ELISA MP-activity assay (r_s=0.42 for both, p<0.05). In addition, endothelial MV levels weakly correlated with white cell counts (r_s = 0.27, p<0.05). Conclusions Thrombin generation and flow cytometry for phosphatidylserine or tissue factor expressing MV correlate well as markers for procoagulant activity. A combination of optical or non-optical enumeration as well as functional methods may be required for a complete profiling of circulating MV.]]> Sat 24 Mar 2018 07:36:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22227 Sat 24 Mar 2018 07:17:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22547 Sat 24 Mar 2018 07:14:44 AEDT ]]>